Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates (OCN/PRF)

This study has suspended participant recruitment.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Régional Metz-Thionville
ClinicalTrials.gov Identifier:
NCT01526915
First received: January 31, 2012
Last updated: April 6, 2017
Last verified: August 2016
  Purpose
The main objective of our study is to assess, after tooth extraction, the efficacity of PRF in the prevention of healing delay and of jawbone osteochemonecrosis induced by bisphosphonates

Condition Intervention
Jawbone Osteochemonecrosis Induced by Bisphosphonates
Procedure: Bone curettage + PRF
Procedure: Bone curettage alone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: Contribution of Platelet Rich Fibrin (PRF) After Tooth Avulsion in the Prevention of Healing Delay and of Jawbone Osteochemonecrosis Induced by Bisphosphonates

Further study details as provided by Centre Hospitalier Régional Metz-Thionville:

Primary Outcome Measures:
  • Delay in cicatrisation at week 8 [ Time Frame: 8 weeks ]
  • The appearance of osteochemonecrosis during the follow-up period [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • The characteristics of the received BP treatment: starting date of ongoing treatment, accumulated dose, type of BP, administration route [ Time Frame: 1 year ]
  • The precise location of the extraction site according to the tooth classification number [ Time Frame: 1 year ]

Estimated Enrollment: 270
Study Start Date: September 2011
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bone curettage + PRF
Bone curettage and PRF insertion
Procedure: Bone curettage + PRF
Bone curettage and PRF insertion
Bone curettage alone
Bone curettage without PRF insertion
Procedure: Bone curettage alone
Bone curettage without PRF insertion

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient major(male or female)
  • Documented indication at the initial visit at day 0 (JO) for a maximum extraction of 3 teeth.
  • Treatment with nitrogenous or non-nitrogenous BP by intravenous injection or oral administration whichever the reason for this drug prescription:

    • on going BP treatment
    • patient having received a previous treatment with bisphosphonates (irrespective of the duration and withdrawal date of this treatment)
  • Patient having received the specific information letter regarding the study and having signed the clarified consent form.

Exclusion Criteria:

  • Patient having a maxillary or mandibulary OCN at Day 0(JO)
  • Positive HIV serology at Day 0(for patients belonging to the PRF group)
  • Previous history of maxillo-cervico-facial radiotherapy
  • Patients with estimated survival expectancy shorter than one year
  • Lack of social security cover
  • Inability of the patient to respect the study follow-up
  • Patient having reached his/her majority and under tutelage,trusteeship or protection of the court
  • Patient whose diagnosis could not be revealed to him/her (especially when the patient or their family expressed this wish).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01526915

Locations
France
Chu de Dijon
Dijon, France, 21033
Scm Bally Curien
Maxeville, France, 54320
Chr Metz Thionville
Metz, France, 57038
Chu de Nancy
Nancy, France, 54035
Chu de Reims
Reims, France, 51092
Sponsors and Collaborators
Centre Hospitalier Régional Metz-Thionville
Investigators
Principal Investigator: Eric GERARD, Dr CHR Metz Thionville
  More Information

Responsible Party: Centre Hospitalier Régional Metz-Thionville
ClinicalTrials.gov Identifier: NCT01526915     History of Changes
Other Study ID Numbers: RBM 2009-01
2009-A01003-54 ( Other Identifier: ID RCB - AFSSAPS )
Study First Received: January 31, 2012
Last Updated: April 6, 2017

Keywords provided by Centre Hospitalier Régional Metz-Thionville:
PRF
PLATELET RICH FIBRIN
BISPHOSPHONATES

Additional relevant MeSH terms:
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 21, 2017